Virtus Fund Advisers’s Halozyme HALO Stock Holding History

Virtus Fund Advisers’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$20.8K	Sell	436 -321	-42%	-$16.5K	0.07%	104
2024 Q3	$43.3K	Hold	757	–	–	0.18%	74
2024 Q2	$39.6K	Buy	757 +7	+0.9%	+$307	0.16%	72
2024 Q1	$30.5K	Hold	750	–	–	0.11%	88
2023 Q4	$27.7K	Hold	750	–	–	0.17%	91
2023 Q3	$28.6K	Hold	750	–	–	0.2%	77
2023 Q2	$27.1K	Hold	750	–	–	0.19%	86
2023 Q1	$28.6K	Hold	750	–	–	0.2%	79
2022 Q4	$42.7K	Buy	+750	New	+$38.4K	0.31%	60
2017 Q4	$981K	Buy	+48,401	New	+$890K	0.01%	290
2014 Q3	–	Sell	-8,823	Closed	-$87K	–	1481
2014 Q2	$87K	Buy	+8,823	New	+$74.9K	﹤0.01%	1492

Other funds holding HALO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Virtus Fund Advisers's HALO Position: Q4 2024 in Review

Virtus Fund Advisers reduced its Halozyme (HALO) stake by 42% in Q4 2024, selling an estimated $16.5K and leaving 436 shares worth $20.8K. The position accounts for 0.07% of the portfolio, ranked #104.

Virtus Fund Advisers first reported a position in HALO in Q2 2014 and has held it in 11 quarters since. The position peaked at $981K in Q4 2017. 508 funds tracked by Wall St. Rank hold HALO as of Q4 2024.

Virtus Fund Advisers held 436 shares of Halozyme worth $20.8K as of Q4 2024.
Virtus Fund Advisers sold 321 Halozyme shares in Q4 2024, an estimated $16.5K.
Halozyme made up 0.07% of Virtus Fund Advisers's portfolio in Q4 2024, its #104 holding.
Virtus Fund Advisers first reported a position in Halozyme in Q2 2014 and has held it in 11 quarters since.
Virtus Fund Advisers's Halozyme position peaked at $981K in Q4 2017.
508 funds tracked by Wall St. Rank held Halozyme as of Q4 2024.

Based on Virtus Fund Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.